{"DataElement":{"publicId":"3361894","version":"1","preferredName":"Initial Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Outcome Value","preferredDefinition":"occurring at the beginning._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_The result of an action._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Init_Labo_Huma_Valu_Huma_Valu","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3361893","version":"1","preferredName":"Initial Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Outcome","preferredDefinition":"occurring at the beginning._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_The result of an action.","longName":"Init_Labo_Huma_Valu","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"3361891","version":"1","preferredName":"Initial Laboratory Procedure","preferredDefinition":"occurring at the beginning.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","longName":"CL052284:C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initial","conceptCode":"CL052284","definition":"occurring at the beginning.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-6A4A-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"ONEDATA","dateModified":"2012-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2779285","version":"1","preferredName":"Human Chorionic Gonadotropin Beta Subunit Outcome","preferredDefinition":"The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104):Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C17479:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriogonadotropin Subunit Beta 3","conceptCode":"C17479","definition":"Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55EAE0D4-E358-1D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-09-02","modifiedBy":"ONEDATA","dateModified":"2008-09-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-6A58-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3361882","version":"1","preferredName":"Human Chorionic Gonadotropin Beta Subunit Value","preferredDefinition":"The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Huma_Valu","context":"NRG","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3361881","version":"1","preferredName":"Human Chorionic Gonadotropin Beta Subunit Value","preferredDefinition":"The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104):A numerical quantity measured or assigned or computed.","longName":"C17479:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriogonadotropin Subunit Beta 3","conceptCode":"C17479","definition":"Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-69BB-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"ONEDATA","dateModified":"2012-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-69CC-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"SBR","dateModified":"2013-08-01","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104991","version":"1","longName":"GOG-0275","context":"NRG"}]}],"AlternateNames":[{"name":"Init_Labo_Huma_Valu_Huma_Valu","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Initial Beta-hCG titer at reg","type":"Preferred Question Text","description":"Initial Beta-hCG titer at registration","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-6A69-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}